6-K ·Filed Jul 23, 2026

RDY

DR REDDYS LABORATORIES LTD
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago SEC0001575872-26-000531
Actionable Insight • Neutral

These filings are routine governance updates with no trading implications. Monitor the next quarterly earnings release for financial performance and any strategic updates from the new independent director, Mr. Srikanth Velamakanni, whose AI expertise could signal a future strategic focus.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d ⚠ clustered
RDY ▲ +2.63% at T+20d
NEUTRAL call ✓ call won +2.63% · α vs SPY -0.68% · entry $11.80 → $12.11
Next anchor: T+60d in 14d
Latest observation: T+48 +33.26% FF3 residual α
Entry anchored
Jul 23, 02:39 PM ET
via exchange tick
T+1d
-0.08%
call -0.08% · α -0.19%
$11.79
settled 2mo ago
T+5d
+0.25%
call +0.25% · α -0.22%
$11.83
settled 2mo ago
T+20d
+2.63%
call +2.63% · α -0.68%
$12.11
settled 6w ago
T+60d
—
call — · α —
—
in 14d

Price Chart

Loading chart...

Executive Summary

Dr. Reddy's filed two 6-Ks on July 23, 2026, reporting the outcome of its 42nd Annual General Meeting. Shareholders approved all resolutions, including the re-appointment of Dr. K P Krishnan as an Independent Director, the appointment of Mr. Srikanth Velamakanni as a new Independent Director, and the appointment of M/s Deloitte Haskins & Sells, LLP as the new statutory auditors. These are routine governance items with no material financial impact, confirming the company's stable corporate governance structure.

Key Facts

  • Shareholders approved all 7 resolutions at the 42nd AGM held on July 23, 2026.
  • Dr. K P Krishnan was re-appointed as an Independent Director for a second term from Jan 7, 2027 to Jan 6, 2032.
  • Mr. Srikanth Velamakanni (Co-Founder & Group CEO of Fractal) was appointed as an Independent Director from July 1, 2026 to June 30, 2031.
  • M/s Deloitte Haskins & Sells, LLP was appointed as Statutory Auditors for a five-year term from the 42nd AGM to the 47th AGM.
  • A final dividend of Rs. 8 per equity share for FY2025-26 was declared.
  • The AGM was held via video conferencing with 86 members holding 22,25,59,764 shares in attendance.

Financial Impact

No financial impact. Routine governance approvals with no new financial disclosures.

Risk Factors

  • No material risks identified from these filings.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
52% bullish (44 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (RDY) — Batch item 10001575872-26-000531
Document: 0001575872-26-000531-index.html0001575872-26-000530
Document: 0001575872-26-000531.txt0001575872-26-000531
6-K Filing (RDY) — Batch item 40001575872-26-000530
Document: 0001575872-26-000530-index.html0001575872-26-000531
Document: 0001575872-26-000530.txt0001575872-26-000531
6-K Filing (RDY) — Batch item 70001575872-26-000531
51 reports for RDY
Performance horizon
67% Hit rate 6 of 9 directional calls best @ T+20▲ +23.28%Jun 26, 2026
Filters
Rows
Reports for RDY — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
6-K
NEUTRAL ★ 3/10
$11.91 $11.55▼ −3.02%▼ −2.56%$12.25 (+2.85%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 5/10
$11.71 $11.90▲ +1.62%▲ +0.77%$12.25 (+4.61%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 2/10
$11.71 $11.90▲ +1.62%▲ +0.77%$12.25 (+4.61%)
Aug 26, 2026
5w ago
6-K
NEUTRAL ★ 2/10
$12.22 $12.16▼ −0.49%▼ −1.15%$12.25 (+0.25%)
Aug 17, 2026
6w ago
6-K
MIXED ★ 5/10
$12.11 $12.15▲ +0.33%▲ +1.01%$12.25 (+1.16%)
Aug 13, 2026
7w ago
6-K
NEUTRAL ★ 3/10
$12.42 $12.27▼ −1.21%▼ −1.01%$12.25 (−1.37%)
Aug 10, 2026
7w ago
6-K
NEUTRAL ★ 2/10
$12.15 $12.45▲ +2.47%▲ +2.79%$12.25 (+0.82%)
Aug 3, 2026
8w ago
6-K
BULLISH ★ 6/10
$12.07 $12.10▲ +0.25%▼ −1.55%$12.25 (+1.49%)
Jul 29, 2026
9w ago
6-K
NEUTRAL ★ 4/10
$11.76 $11.83▲ +0.60%▼ −1.08%$12.25 (+4.17%)
Jul 23, 2026
10w ago
6-K
NEUTRAL ★ 2/10
$11.80 $11.79▼ −0.08%▼ −0.19%$12.25 (+3.81%)
Showing 10 of 51

US Market Status

Market Closed — Opens Mon (65h 27m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access